Serum level of interleukin‐35 as a potential prognostic factor for gastric cancer. Issue 1 (12th October 2020)

• Record Type: Journal Article
• Authors: Gu, Jin‐Hua; Wang, Xiao‐Ge; Wang, Li‐Qiang; Zhou, Li‐Na; Tang, Min; Li, Ping; Wu, Xiao‐Yang; Chen, Min‐Bin; Zhang, Yan
• Is Part Of: Asia-Pacific journal of clinical oncology. Volume 17:Issue 1(2021)
• Page Start: 52
• Page End: 59
• Publication Date: 2020-10-12
• Subjects: cytokine -- gastric cancer -- immune -- interleukin‐35 -- prognosis; Oncology -- Pacific Area -- Periodicals; Cancer -- Treatment -- Pacific Area -- Periodicals; Cancer -- Pacific Area -- Periodicals; Cancer -- Treatment -- Periodicals; 616.9940095
• DOI: 10.1111/ajco.13403
• Languages: English
• ISSNs: 1743-7555

Abstract

Abstract: Aims: Interleukin‐35 (IL‐35), a novel anti‐inflammatory cytokine, has recently been implicated in tumor development, progression, and survival. However, the relationship between serum IL‐35 levels and gastric cancer (GC) is inconclusive. Here, we performed this study to clarify the role of serum level of IL‐35 in GC patients. Methods: We enrolled 180 GC patients and 170 healthy controls and used enzyme‐linked immunosorbent assay to detect serum IL‐35 levels. The clinical relevance between IL‐35 and clinical pathology parameters was assessed. Univariate and multivariate logistic regressions were used to determine the feasibility of IL‐35 as a clinical biomarker. Results: We observed that serum IL‐35 levels were significantly higher in GC patients (17.559 ± 13.266 pg/mL) than in healthy controls (8.077 ± 3.801 pg/mL, P < .001). High serum IL‐35 levels were significantly associated with clinical stage ( P = .048) and Helicobacter pylori (HP) infection ( P < .001). The Kaplan‐Meier survival analysis indicated that patients in the high‐IL‐35 group had poor overall survival (OS) and progression‐free survival (PFS) (median OS: 26.0 vs 36.0 months, P < .001; median PFS: 18.0 vs.26.0 months, P = .044). Multivariate analyses demonstrated that serum IL‐35 was an independent prognostic factor for GC (OS: hazard ratio [HR] = 1.031 [95% CI, 1.017‐1.045], P < .001; PFS: HR = 1.029 [95% CI, 1.015‐1.043], P < .001). Conclusions: High serum IL‐35 levels are associated with poor disease prognosis in GC patients, and it may be become a new and promising biomarker for prognosis of gastric cancer.